Company news
Quest Pharmatech Inc. (TSXV:QPT) news
Quest Pharmatech Inc. news releases on 6ix. Latest, Nov 14, 2016: Bellus Skin Rejuvenation Serum: Quest PharmaTech Launches Scientifically Proven, Clinically…
Press releases — page 2
Bellus Skin Rejuvenation Serum: Quest PharmaTech Launches Scientifically Proven, Clinically Validated Premium Skin Care Cosmetics in Canada
November 14, 2016
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer
November 2, 2016
Quest PharmaTech Inc. Announces Change of Auditor
October 28, 2016
Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model
October 20, 2016
Quest PharmaTech Inc. Amends Warrant Terms
September 16, 2016
/C O R R E C T I O N from Source -- Quest PharmaTech Inc./
September 6, 2016
Quest PharmaTech Announces Filing of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016
August 4, 2016
Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China
March 22, 2016
Quest PharmaTech Announces Results from its 2015 AGM
December 1, 2015
Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer
November 18, 2015
Quest PharmaTech Closes $2,000,000 Private Placement With Hepalink USA
October 13, 2015
Quest PharmaTech Closes $1,000,000 Private Placement
July 27, 2015
Quest PharmaTech Announces Results from its 2014 AGM
November 10, 2014
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin(TM); Dr. Jacqueline Shan, Creator of COLD FX®, to Assist
October 22, 2014
Quest PharmaTech Provides Financial Update
September 16, 2014
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer
June 9, 2014
Quest PharmaTech Announces Third Combinatorial Immunotherapy Clinical Trial for Oregovomab with a TLR3 agonist, Hiltonol®
January 29, 2014
Quest PharmaTech Announces $1,000,000 Non-Brokered Private Placement
November 21, 2013
Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to present late-breaking data at the 28th Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8 - 10, 2013 in Maryland, U.S.
November 7, 2013
Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer
July 23, 2013
Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti - PSA IgE preclinical data at the 2013 American Association for Cancer Research Conference
April 8, 2013
Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.
January 22, 2013
Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer
October 2, 2012
Quest PharmaTech Announces Results from its 2012 AGM
July 31, 2012
Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy
July 10, 2012
Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States
June 14, 2012
Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs
June 5, 2012
Quest PharmaTech Announces Financial Results for 2011
May 23, 2012
Quest PharmaTech Announces $500,000 Non-Brokered Private Placement
May 14, 2012
Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology
November 29, 2011
Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)
November 1, 2011
Quest PharmaTech Announces Closing of $600,000 Non-Brokered Private Placement
October 25, 2011
Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment of Cancer
July 21, 2011
Quest PharmaTech Provides Oregovomab Chemo Immunotherapy Clinical Trial and other Corporate Updates
June 7, 2011
Quest PharmaTech Announces Clinical Development Agreement with Hemispherx Biopharma Inc. to evaluate a combinatorialImmunotherapy Technology
April 14, 2011
Quest PharmaTech Announces Treasury Issue of Common Shares
October 25, 2010
Quest PharmaTech Announces Formation of Clinical Advisory Panel
July 9, 2010
Quest PharmaTech Announces 2010 Financial and Operational Results
May 19, 2010
Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
May 11, 2010
Oregovomab: Quest PharmaTech Discloses Cancer Immunotherapy Development Strategy
April 6, 2010
Quest PharmaTech Announces Securing of $1,000,000 Debt Financing
February 4, 2010
Quest PharmaTech Announces the Results of its January 26, 2010 AGM
February 1, 2010
Quest PharmaTech Announces the Passing of One of its Directors
November 13, 2009
AllPennyStocks.com News: Junior Pharma Company Picks Up Antibody Platform From Major (QPT.V)
October 1, 2009
Investment Industry Regulatory Organization of Canada - Trade Resumption - Quest Pharmatech Inc - QPT
September 30, 2009
Quest PharmaTech Announces Second Quarter Results
September 15, 2009
Quest PharmaTech Announces First Quarter Results
June 17, 2009
Quest PharmaTech Announces 2009 Financial and Operational Results
May 20, 2009
Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
March 18, 2009
Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
March 4, 2009